China's Wanbang Licenses New Class Of Diabetes Drug From Sirona
This article was originally published in PharmAsia News
Executive Summary
Wanbang Pharma has signed a $9.5 million licensing deal for Sirona Biochem's new class of drug believed capable of treating Type 2 diabetes.